Abstract
New and more transmissible variants of SARS-CoV-2 have arisen multiple times over the course of the pandemic. Rapidly identifying mutations that affect transmission could improve our understanding of viral biology and highlight new variants that warrant further study. Here we develop a generic, analytical epidemiological model to infer the transmission effects of mutations from genomic surveillance data. Applying our model to SARS-CoV-2 data across many regions, we find multiple mutations that substantially affect the transmission rate, both within and outside the Spike protein. The mutations that we infer to have the largest effects on transmission are strongly supported by experimental evidence. Importantly, our model detects lineages with increased transmission even at low frequencies. As an example, we infer significant transmission advantages for the Alpha, Delta, and Omicron variants shortly after their appearances in regional data, when their local frequencies were only around 1-2%. Our model thus facilitates the rapid identification of variants and mutations that affect transmission from genomic surveillance data.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The work of B.L., E.F., and J.P.B. reported in this paper was supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number R35GM138233. The work of S.F.A., M.S.S., A.A.Q., and M.R.M. was supported by the General Research Fund of the Hong Kong Research Grants Council under Grant Number 16213121.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
This update includes more than two years of additional SARS-CoV-2 sequence data and an extensive investigation of the experimental support for the mutations that we infer to strongly affect viral transmission. We have edited the entire manuscript for clarity, added new analyses, and updated author affiliations and supplemental data.
Data Availability
Sequence data and metadata used in this study are available from GISAID. Processed data and code are available in the linked GitHub repository.
